 Drug Resistance, Viral
"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.320.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 3 | 4 | | 2003 | 2 | 3 | 5 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 3 | 0 | 3 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 0 | 2 | | 2010 | 2 | 0 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 2 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 0 | 2 | 2 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Mukerji SS, Misra V, Lorenz D, Cervantes-Arslanian AM, Lyons J, Chalkias S, Wurcel A, Burke D, Venna N, Morgello S, Koralnik IJ, Gabuzda D. Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults. J Acquir Immune Defic Syndr. 2017 06 01; 75(2):246-255.
-
Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119.
-
Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease. Transplant Proc. 2016 Jul-Aug; 48(6):2056-2064.e1.
-
Reau N, Fried MW, Nelson DR, Brown RS, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
-
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
-
Gagermeier JP, Rusinak JD, Lurain NS, Alex CG, Dilling DF, Wigfield CH, Love RB. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014 Dec; 16(6):941-50.
-
Parkin N, Bremer J, Bertagnolio S. Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. Clin Infect Dis. 2012 May; 54 Suppl 4:S266-72.
-
Parkin N, de Mendoza C, Schuurman R, Jennings C, Bremer J, Jordan MR, Bertagnolio S. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin Infect Dis. 2012 May; 54 Suppl 4:S273-9.
-
Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
-
Leung MY, Cohen FS. Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency. Biophys J. 2011 Apr 20; 100(8):1960-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|